Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 4-((3s,3as)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo(3,4-f)quinolin-2-yl)-2-chlorobenzonitrile
2. Kbp-5074
1. Ocedurenone [inn]
2. Kbp5074
3. Kbp-5074
4. L46509378r
5. 1359969-24-6
6. 2-chloro-4-((3s,3ar)-3-cyclopentyl-7-((4-hydroxy-1-piperidinyl)carbonyl)-3,3a,4,5-tetrahydro-2h-pyrazolo(3,4-f)quinolin-2-yl)benzonitrile
7. Benzonitrile, 2-chloro-4-((3s,3ar)-3-cyclopentyl-3,3a,4,5-tetrahydro-7-((4-hydroxy-1-piperidinyl)carbonyl)-2h-pyrazolo(3,4-f)quinolin-2-yl)-
8. Schembl15048760
9. Gtpl12040
10. Unii-l46509378r
11. Example 12 [us9468635b2]
12. Hy-132827
13. Cs-0204111
14. 4-[(3s,3ar)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile
| Molecular Weight | 504.0 g/mol |
|---|---|
| Molecular Formula | C28H30ClN5O2 |
| XLogP3 | 4.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 6 |
| Rotatable Bond Count | 3 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 92.8 |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 905 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
KBP-5074 (ocedurenone) is a non-steroidal, mineralocorticoid receptor antagonist, was in development for patients with uncontrolled hypertension in patients with advanced chronic kidney disease.
Lead Product(s): Ocedurenone
Therapeutic Area: Nephrology Brand Name: KBP-5074
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2024
Lead Product(s) : Ocedurenone
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Novo Nordisk stops the ocedurenone CLARION-CKD trial and recognises impairment loss
Details : KBP-5074 (ocedurenone) is a non-steroidal, mineralocorticoid receptor antagonist, was in development for patients with uncontrolled hypertension in patients with advanced chronic kidney disease.
Brand Name : KBP-5074
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 26, 2024
Details:
Through the acquisition, Novo Nordisk gains access to KBP-5074 (ocedurenone), an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA), for uncontrolled hypertension with potential application in cardiovascular and kidney disease.
Lead Product(s): Ocedurenone
Therapeutic Area: Nephrology Brand Name: KBP-5074
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Novo Nordisk
Deal Size: $1,300.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 16, 2023
Lead Product(s) : Ocedurenone
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Novo Nordisk
Deal Size : $1,300.0 million
Deal Type : Acquisition
Novo Nordisk to Acquire Ocedurenone for Uncontrolled Hypertension from KBP Biosciences
Details : Through the acquisition, Novo Nordisk gains access to KBP-5074 (ocedurenone), an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist (nsMRA), for uncontrolled hypertension with potential application in cardiovascular ...
Brand Name : KBP-5074
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 16, 2023
Details:
KBP-5074 (ocedurenone) is a non-steroidal MRA which selectively binds to recombinant human MRs with much higher affinity than to recombinant human glucocorticoid, progesterone, and androgen receptors which can produce antihypertensive, renal and cardioprotective effects.
Lead Product(s): Ocedurenone
Therapeutic Area: Nephrology Brand Name: KBP-5074
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2023
Lead Product(s) : Ocedurenone
Therapeutic Area : Nephrology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : KBP-5074 (ocedurenone) is a non-steroidal MRA which selectively binds to recombinant human MRs with much higher affinity than to recombinant human glucocorticoid, progesterone, and androgen receptors which can produce antihypertensive, renal and cardiopr...
Brand Name : KBP-5074
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 06, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?
Market Place
